A private intelligence platform identifying overlooked drug repurposing opportunities across 23 disease conditions
Ouki is a private drug repurposing intelligence platform operating across 23 disease conditions. It identifies novel connections between existing approved drugs and unexplored treatment applications — surfacing opportunities that cross-disciplinary research has not yet reached.
The problem: Mechanistically significant drug repurposing opportunities remain undiscovered across the breadth of published medical science. The scale of the problem exceeds what any research team can monitor.
What Ouki does: Surfaces proprietary, mechanistically grounded drug repurposing hypotheses — each identifying a specific approved drug, a new indication, and the precise gap in existing research.
Who it is for: Pharmaceutical companies, biotech firms, and research institutions under commercial agreement. Access is not publicly available.
Drug repurposing — identifying new therapeutic applications for existing FDA-approved medications — offers substantial advantages over novel drug development:
The commercial and clinical case for drug repurposing is well established. The bottleneck is systematic identification of credible opportunities — which is precisely what Ouki addresses.
Ouki currently monitors 23 major disease conditions:
Coverage is expanded selectively based on therapeutic area demand from partner organisations.
Ouki is a computational hypothesis generation platform. The following limitations apply to all findings:
Ouki is designed to accelerate the early stages of drug repurposing research by surfacing mechanistically grounded hypotheses for expert evaluation — not to replace the rigorous scientific and regulatory process that follows.
All Ouki findings are cryptographically timestamped using distributed version control at the point of generation, establishing immutable proof of discovery date and priority.
Each finding carries a verifiable cryptographic record proving its existence at a specific date and time. This timestamped archive is maintained as definitive proof of intellectual priority and is available for verification by authorised parties under appropriate agreement.
All findings generated by the Ouki platform are the proprietary intelligence of Ouki Research. Access to, and any commercial use of, Ouki findings is subject to the terms of a signed commercial agreement. Unauthorised use of Ouki intelligence for commercial purposes is prohibited.
Ouki findings are available to qualifying pharmaceutical companies, biotech firms, and research institutions under commercial licensing agreement.
Access is not publicly available. Enquiries from organisations interested in accessing Ouki's drug repurposing intelligence — including therapeutic area-specific findings, custom condition analysis, and ongoing pipeline access — should be directed to:
All substantive enquiries will be progressed under a Non-Disclosure Agreement prior to any findings being shared.
Ouki generates research hypotheses, not medical advice.
All findings on this platform are computational predictions that require validation by qualified medical researchers through proper clinical studies. Nothing on this site should be interpreted as medical advice, treatment recommendations, or established scientific fact.
If you are a patient or caregiver, please consult qualified healthcare professionals for medical guidance.
Ouki was developed by a cancer survivor and mechanical & electrical engineer who transitioned into software engineering with expertise in AI systems and automation. Having navigated the healthcare system firsthand and witnessed the challenges of cross-disciplinary medical research, the developer combined engineering problem-solving with AI to build a platform that identifies overlooked connections across disease boundaries at a scale no individual researcher can match.
The name "Ouki" (大喜) means "great joy" in Japanese — reflecting the conviction that accelerating drug repurposing discovery can bring genuine relief to those living with conditions that medicine has not yet adequately addressed.
For commercial enquiries, partnership discussions, or verified researcher access, contact: ouki.research@proton.me